Streetbeat News

Analyst Ratings

REPL

Over the past 3 months, 9 analysts have published their opinion on Replimune Group (NASDAQ:REPL) stock. The average price target is $54.11, implying an upside from the current price of $21.12. The majority of the ratings are bullish, with 6 out of 9 analysts giving a positive outlook.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 9:21 am

MS

Over the past 3 months, 7 analysts have published their opinion on Morgan Stanley (NYSE:MS) stock. The average 12-month price target for Morgan Stanley is $96.14, with a high of $110.00 and a low of $90.00. The average price target has increased by 1.41% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 9:21 am

URBN

Urban Outfitters (NASDAQ:URBN) has received a mix of bullish and indifferent analyst ratings in the last quarter. According to 11 analysts, the average 12-month price target for the company is $34.82, with a high of $45.00 and a low of $29.00. This average price target has increased by 16.07% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 9:20 am

EW

Edwards Lifesciences (NYSE:EW) has received positive analyst ratings in the last quarter, with 13 bullish and 8 somewhat bullish ratings. The company has an average 12-month price target of $101.46, which has increased by 1.32% over the past month.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 9:20 am

CC

Morgan Stanley analyst Vincent Andrews has reiterated an Equal-Weight rating on Chemours (NYSE:CC) and maintained a $33 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:20 am

FUN

Morgan Stanley analyst Thomas Yeh has maintained an Overweight rating on Cedar Fair (NYSE:FUN) but lowered the price target from $53 to $48.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:20 am

CHTR

Morgan Stanley analyst Benjamin Swinburne has reiterated an Equal-Weight rating on Charter Communications (NASDAQ:CHTR) and maintained a price target of $460.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:20 am

BNTX

Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $119.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:19 am

BMRN

Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $129 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:19 am

AVNT

Morgan Stanley analyst Angel Castillo has reiterated an Equal-Weight rating on Avient (NYSE:AVNT) and maintained a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:19 am